G - CON and GE Healthcare developed a platform to help drug developers manufacture materials which combined G - CON 's prefabricated flexible manufacturing facilities ( PODs ) with hp 's cell therapy and viral vectors technology . The platform would work to streamline the delivery of drugs from clinical trials to general markets . The demand for cell and gene therapy was growing , but the availability of elements like viral vectors was not meeting the demand . GE Healthcare said it was also investing to improve its own ability to produce cell therapy materials .
G-CON and GE Healthcare launched a platform to help drug developers manufacture materials which combined G-CON's prefabricated flexible cleanroom facilities (PODs) with GE's cell therapy and viral vectors technology. The platform would work to streamline the progression of drugs from clinical trials to general markets. The demand for cell and gene therapy was growing, but the production of elements like viral vectors was not meeting the demand. GE Healthcare said it was also investing to improve its own ability to produce cell therapy materials.